EMADOC-1700519818-1796802

European Medicines Agency decision

EMA/PE/0000182075

of 3 January 2025

on the acceptance of a modification of an agreed paediatric investigation plan for Venetoclax (Venclyxto) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

EMA/PE/0000182075

of 3 January 2025

on the acceptance of a modification of an agreed paediatric investigation plan for Venetoclax (Venclyxto) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0235/2017 issued on 9 August 2017, the decision P/0001/2019 issued on 4 January 2019, the decision P/0246/2019 issued on 17 July 2019, the decision P/0375/2020 issued on 9 September 2020, the decision P/0217/2021 issued on 9 June 2021, and the decision P/0148/2022 issued on 13 May 2022,

Having regard to the application submitted by Abbvie Limited on 10 August 2024 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 15 November 2024, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for Venetoclax (Venclyxto), are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Abbvie Limited, Abbvie House, 2 Vanwall Road, Maidenhead, SL6 4UB, United Kingdom.

EMADOC-1700519818-1661812
Amsterdam, 15 November 2024

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMA-PE-0000182075

Scope of the application

Active substance(s):

Venetoclax

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue

Treatment of solid malignant tumours

Pharmaceutical form(s):

Powder for oral suspension

Tablet for oral suspension

Film-coated tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

AbbVie Ltd

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, AbbVie Ltd submitted to the European Medicines Agency on 10 August 2024 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0235/2017 issued on 9 August 2017, the decision P/0001/2019 issued on 4 January 2019, the decision P/0246/2019 issued on 17 July 2019, the decision P/0375/2020 issued on 9 September 2020, the decision P/0217/2021 issued on 9 June 2021, and the decision P/0148/2022 issued on 13 May 2022.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 16 September 2024.

Scope of the modification

Some timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition

Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue

2.1.1. Indication(s) targeted by the PIP

Treatment of relapsed or refractory acute lymphocytic leukaemia (ALL)

Treatment of relapsed or refractory acute myeloid leukaemia (AML)

Treatment of relapsed or refractory non-Hodgkin lymphoma (NHL)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Tablet for oral suspension

Powder for oral suspension

2.1.4. Measures

Area	Description
Quality-related studies	**Study 1** Development of an age-appropriate tablet for oral suspension. **Study 6** Development of an age-appropriate powder for oral suspension. *(introduced during EMEA-002018-PIP02-16-M05)*
Non-clinical studies	**Study 2** Definitive juvenile toxicity study to determine the potential effects of venetoclax on development.
Clinical studies	**Study 3 (M13-833)** Open-label dose determination (Part 1) and cohort expansion (Part 2) study in paediatric patients from birth to 18 years old (and young adults) with select relapsed or refractory solid and haematologic malignancies.

	Study 4 *deleted during EMEA-002018-PIP02-16-M04* **Study 5 (B19-061)** *(introduced during EMEA-002018-PIP02-16-M04)* Randomized, open label, controlled, global study to evaluate the efficacy of venetoclaxin combination with fludarabine and high dose cytarabine, and gemtuzumab ozogamicincompared with fludarabine and high dose cytarabine and gemtuzumab ozogamicin alone in children with relapsed acute myeloid leukaemia without FLT3/ITD mutation.
Extrapolation, modelling and simulation studies	Not applicable.
Other studies	Not applicable.
Other measures	Not applicable.

2.2. Condition

Treatment of solid malignant tumours

2.2.1. Indication(s) targeted by the PIP

Treatment of patients with relapsed or refractory neuroblastoma in patients from birth to less than 18 years of age.

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.2.3. Pharmaceutical form(s)

Film-coated tablet

Tablet for oral suspension

Powder for oral suspension

2.2.4. Measures

Area	Description
Quality-related studies	**Study 1** The same as for condition "Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue". **Study 6** The same as for condition "Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue".

Non-clinical studies	**Study 2** The same as for condition "Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue".
Clinical studies	**Study 3 (M13-833)** The same as for condition "Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue". **Study 4** Evaluation of efficacy of venetoclax in paediatric patients from birth to less than 18 years of age (and young adults) with select paediatric solid or haematologic tumour type prioritized based on anti-tumour activity in study M13-833 (study 3).
Extrapolation, modelling and simulation studies	Not applicable.
Other studies	Not applicable.
Other measures	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long-term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2029
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s):

1. Treatment of malignant neoplasms of the haematopoietic tissue

Authorised indications:

- Venclyxto monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.
- Venclyxto monotherapy is indicated for the treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemo-immunotherapy and a B-cell receptor pathway inhibitor.
- Venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.
- Venclyxto in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.
- Venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.

Authorised pharmaceutical form(s):

Film-coated tablet

Authorised route(s) of administration:

Oral use